Phytochemical Screening and Isolation of New Ent-Clerodane Diterpenoids from Croton guatemalensis Lotsy

Sonia Marlen Escandón-Rivera¹*, Adolfo Andrade-Cetto¹, Daniel Genaro Rosas-Ramírez²* and Roberto Arreguín-Espinosa²*

¹ Departamento de Biología Celular, Facultad de Ciencias, Universidad Nacional Autónoma de México, Av. Universidad 3000, Circuito Exterior S/N, Coyoacán, Ciudad Universitaria, Mexico City 04510, Mexico
² Departamento de Biomacromoléculas, Instituto de Química, Universidad Nacional Autónoma de México, Av. Universidad 3000, Circuito Exterior S/N, Coyoacán, Ciudad Universitaria, Mexico City 04510, Mexico
* Correspondence: aac@ciencias.unam.mx; Tel.: +52-5556225437

Abstract: Phytochemical screening of an ethanol–water extract (EWE) from the bark of Croton guatemalensis led to the isolation and identification of eight compounds, among them: five ent-clerodane diterpenoids [junceic acid (1), 6(s)-acetoxy-15,16-diepoxy-ent-cleroda-3,13(16),14-trien-20-oic acid (crotopuguatenico acid A) (2), 6(s)-hydroxyoxy-15,16-diepoxy-ent-cleroda-3,13(16),14-trien-20-oic acid (crotopuguatenico acid B) (3), formosin F (4), bartsiifolic acid (5)], and three flavonoids [rutin (6), epicatechin (7), and quercetin (8)]. Of these, 2 and 3 are reported here for the first time. Structures were established through conventional spectroscopy methods and their absolute configurations were determined by optical rotation and comparison of experimental electronic circular dichroism (ECD) and theoretical calculated ECD spectra. A suitable high performance liquid chromatography (HPLC) method for quantifying rutin (6) was developed and validated according to standard protocols. Affinity-directed fractionation was used to identify possible in vitro active compounds on α-glucosidases from Saccharomyces cerevisiae. HPLC-ESI-MS was used to identify the inhibitors as free ligands after being released from the enzymatic complex by denaturing acidic conditions. The affinity studies led to the identification of ent-clerodane diterpenoids as active compounds. In silico analysis allowed us to determine the best conformational rearrangement for the α-glucosidase inhibitors.

Keywords: Croton guatemalensis; ent-clerodane diterpenoid; circular dichroism; HPLC quantification; α-glucosidase inhibitor; docking

1. Introduction

About 1300 species of the Croton genus (Euphorbiaceae) were reported, which are distributed in tropical climate regions around the world [1]. Extracts of different parts of the plant (aerial parts, roots, leaves, bark, etc.) are used for the treatment of various ailments, such as stomachache, abscesses, inflammation, cancer, diabetes, and malaria in the Americas, Africa, and South Asia [1–3]; for example, in an in vivo assay of the ethanolic extract of the aerial parts of C. zambesicus was performed to determine antiplasmodial activity against chloroquine-sensitive Plasmodium berghei infections in mice [4], crude leaf extracts of Croton cajucara exhibited a significant antinociceptive effect in rats. The cortex bark is one of the most used parts of pharmacological interest and was studied as an analgesic, anti-inflammatory, antiulcerogenic, gastroprotective, antiviral, antibacterial, antitumor, and hypoglycemic agent [2,3,5]. Many compounds were isolated and identified, among the most important are terpenes, and within them the diterpenes with different types of skeletons are the predominant group, with more than 800 registered compounds, including clerodane, tigliane, kaurane, clerofolane, labdane, embrane, abietane, casbane, halimane, pimaran, cleistanthane, grayanane, atisane, phytyne, and laevinane diterpenoids; of which clerodanes are the most abundant [1,2]. Some alkaloids and phenolic compounds were also...
isolated. Recent interest in searching for flavonoids in this genus led to the identification of proanthocyanidins, flavones, glycosylated flavonols, and lignans; among the most common are rutin, quercetin, kaempferol, catechin, and epicatechin [6–9], which could serve as genus chemical markers. Finally, the essential oils of various Croton species present α-pinene, β-pinene, camphor, 1,8 cineole, and germacrenes among their most abundant compounds [10–14].

**Croton guatemalensis**Lotsy (Cg) is a small tree, up to 6 m high, distributed in the tropical and subtropical areas of the Americas, including Mexico, Colombia, Ecuador, and Guatemala; it is also known as “copalchi”. Aqueous and methanolic extracts of leaves and cortex were reported as antiplasmodial and cytotoxic [15]; whereas the aqueous extract of the bark is antinociceptive [16]. Our group proved that the aqueous and hydroalcoholic extracts have hypoglycemic activity [17]; so far, no compounds isolated from the plant are reported. In this research, the EWE, such as the one used in the previous work, from the bark of *C. guatemalensis* was fractionated to isolate the main compounds to provide information about its chemical profile; furthermore, with the aim to understand the ecological role of some of the isolated compounds affinity studies for the identification of new α-glucosidase inhibitors were performed.

**2. Results and Discussion**

**2.1. Isolation and Identification of Previously Undescribed Compounds**

The ethanol–water extract (EWE) from *C. guatemalensis* was subjected to fractionation procedures to obtain five ent-clerodane diterpenes [junceic acid (1), 6(s)-acetoxy-15,16-diepoxy-ent-cleroda-3,13(16),14-trien-20-oic acid (crotoguatenoic acid A) (2), 6(s)-hydroxyoxy-15,16-diepoxy-ent-cleroda-3,13(16),14-trien-20-oic acid (crotoguatenoic acid B) (3), formosin F (4), bartsiifolic acid (5)], and three flavonoids [rutin (6), epicatechin (7), and quercetin (8)] (Figure 1). Of these, two diterpenes were not previously described (2 and 3), whereas 1, 4, 5, and 7 were identified based on comparisons of their 1H and 13C-NMR spectral data, including data obtained in 2D experiments (COSY, HSQC, HMBC, NOESY, and TOCSY) and their mass spectral data, with those of previously described compounds [18–21]. Flavonoids 6 and 8 were analyzed by HPLC, and their retention time and UV spectra were compared with standards (>94% HPLC; Sigma-Aldrich) of rutin (6) and quercetin (8), respectively.

![Figure 1. Structure of isolated compounds 1 to 8.](image-url)

Compound 2 was obtained as white powder, with a melting point of 96 to 100 °C and molecular formula C22H30O5 derived by NMR spectroscopy data and the ESI-MS ion at 397.4 [M + Na]+ and HRESIMS ion at 373.1813 [M–H]− (calcd. for C22H29O5, 373.2020), suggesting eight degrees of unsaturation (Figures S1–S10). The IR spectrum (Figure S11) exhibited a broad absorption band of hydroxyl (3380 cm⁻¹), conjugated
carbonyl (1714 cm\(^{-1}\) of a carboxylic acid and 1693 cm\(^{-1}\) of carbonyl ester), and double bond (1408, 1358, and 1372 cm\(^{-1}\)) functional groups. The \(^1\)H, \(^13\)C, and DEPT spectra (Table 1; Supplementary Data, Figures S1–S3) showed the presence of a 22-carbon entity including four methyls, five methylenes, three methines, six vinylic, and four quaternary carbons; \(^1\)H and \(^13\)C spectra (Table 1, Figures S1 and S2), HSQC (Figure S4), and COSY (Figure S5) correlations showed typical signs of a clerodane skeleton, diterpene, with three methyl groups, as part of the base skeleton at \(\delta_{C/H}\) 13.9/1.09 (s; C/H-19), 16.1/1.14 (d, \(J = 6.69\) Hz; C/H-17), and 21.2/1.59 (br s; C/H-18); and a methyl acetate as a radical at \(\delta_{C/H}\) 22.0/2.04 (s) in the B ring of decalin; two pairs of carbons are part of characteristic signals of a furan ring at \(\delta_{C/H}\) 110.9/6.26 (dd, \(J = 1.83, 0.90\) Hz; C/H-14), 124.4 (C-13), 138.7/7.23 (dd, \(J = 1.61, 0.88\) Hz; C/H-16), and 143.1/7.35 (t, \(J = 1.69\) Hz; C/H-15). The chemical shift of the double bond between \(\delta_{C/H}\) 123.6/5.30 (dd; \(J = 2.87, 1.39\) Hz; C/H-3) and \(\delta_{C}\) 141.5 (C-4) indicates the absence of any substituent at C-18. The carboxyl group noted at \(\delta_{C}\) 182.3, which presented HMBC correlation (Figures 2a and S6) with H-10 (\(\delta_{H}\) 1.66; d, \(J = 11.50\) Hz) and H-8 (\(\delta_{H}\) 1.76; m), demonstrates its unequivocal position at C-20. The relative configuration of 2 was possible by the NOESY spectrum (Figure S7), and these data showed NOESY correlations (Figure 2b) of H-6 with H-10 and H-8, suggesting the beta position; simultaneously, H-10 with H-12 (\(\delta_{H}\) 2.33; m) and H-19 (\(\delta_{H}\) 1.09; s) with H-7\(\alpha\) (\(\delta_{H}\) 2.20; m), indicating a trans-cis-type clerodane skeleton configuration, as occurs in most of these diterpenes [22]. These signals were similar to those of the isolated ent-clerodane diterpene junceic acid (1) [18]. However, the main difference was the H-6 deshielded at \(\delta_{H}\) 4.73 (dd, \(J = 11.34, 5.0\) Hz), which presented HMBC correlation (Figure 2a) with the acetate moiety (\(\delta_{C}\) 22.0) and TOCSY correlation (Figure S8) with \(\delta_{H}\) 2.20 (m, H-7\(\alpha\)), 1.76 (m, H-7\(\beta\)), and 1.14 (d, \(J = 6.69\) Hz, H-17).

**Figure 2.** (a) \(^1\)H-\(^1\)H COSY and key HMBC (H—C) correlations of compound 2; (b) Key NOESY correlations of compound 2.
Table 1. $^1$H and $^{13}$C NMR spectroscopy data of compounds 2 and 3 ($\delta$ in ppm, $J$ in Hz).

| Position | $\delta_1$ a | $\delta_2$ a | $\delta_3$ a | $\delta_4$ a |
|----------|--------------|--------------|--------------|--------------|
| 1        | $\alpha$ 1.85 b, m | $\beta$ 1.93 b, m | 19.8 | $\alpha$ 1.84 b, m | $\beta$ 1.93 b, m | 20.1 |
| 2        | $\alpha$ 1.99 b, m | $\beta$ 2.07 b, m | 27.1 | $\alpha$ 2.02 b, m | $\beta$ 2.10 b, m | 27.2 |
| 3        | 5.30, dd (2.87, 1.39) | 123.6 | 5.31, m | 123.1 |
| 4        | - | 141.5 | - | 143.0 |
| 5        | - | 42.9 | - | 44.7 |
| 6        | 4.73 dd (11.34, 5.00) | 78.2 | 3.59, dd (11.35, 4.97) | 76.1 |
| 7        | $\alpha$ 2.20 b, m | $\beta$ 1.76 b, m | 33.0 | $\alpha$ 2.20 b, dd (13.71, 2.26) | $\beta$ 1.70 b, m | 37.4 |
| 8        | 1.76 b, m | 34.3 | 1.71 ddd (14.06, 6.21, 3.58) | 34.7 |
| 9        | - | 49.3 | - | 49.4 |
| 10       | 1.66, d (11.50) | 47.1 | 1.58 dd (11.63, 1.30) | 47.2 |
| 11       | $\alpha$ 1.85 b, m | $\beta$ 2.26 b, m | 33.9 | $\alpha$ 1.93, m | $\beta$ 2.26 b, m | 34.0 |
| 12       | 2.33 b,c, m | 17.8 | 2.33 b,c, m | 17.8 |
| 13       | - | 124.4 | - | 124.5 |
| 14       | 6.26, dd (1.83, 0.90) | 110.9 | 6.26, dd (1.83, 0.95) | 110.9 |
| 15       | 7.35, t (1.69) | 143.1 | 7.35, t (1.69) | 143.0 |
| 16       | 7.23, dd (1.61, 0.88) | 138.7 | 7.23, dd (1.62, 0.91) | 138.7 |
| 17       | 1.14, d (6.69) | 16.1 | 1.15, d (6.71) | 16.3 |
| 18       | 1.59, br s | 21.2 | 1.84, br s | 22.6 |
| 19       | 1.09, s | 13.9 | 0.98, s | 12.8 |
| 20       | - | 182.3 | - | 181.9 |
|-OAc     | 2.04 | 22.0 | - | - |

a Data recorded at 400 MHz ($^1$H) and 150 MHz ($^{13}$C) in CDCl$_3$. b Overlapped signals. c Signals for two protons.

Compound 3 was isolated as white powder with a melting point of 154 to 156 °C and molecular formula C$_{20}$H$_{28}$O$_4$ derived by NMR spectroscopy data and the HRES-IMS ion at 333.20515 [M + H]$^+$ (calcd. for C$_{20}$H$_{29}$O$_4$, 333.20658) (Figures S12–S21), suggesting seven degrees of unsaturation. The IR spectrum (Figure S22) exhibited an absorption band of hydroxyl (3399 cm$^{-1}$), conjugated carbonyl (1695 cm$^{-1}$), and double bond (1450 and 1376 cm$^{-1}$) functional groups. The $^1$H- and $^{13}$C- NMR data of 3 (Table 1, Figures S12 and S13) indicated a diterpenoid of the clerodane class, which was supported by the DEPT, 2D HSQC, COSY, HMBC, NOESY, and TOCSY experiments (Figures S14–S19), showing a close relationship with compound 2 (Table 1). The only difference was the functional group at C-6 with a hydroxyl with chemical shift at $\delta_H$ 3.59 (dd, $J = 11.35, 4.97$ Hz, H-6) instead of an acetate. The position of this hydroxyl was corroborated with the HMBC spectrum (Figure S17), which shows HMBC correlation (Figure 3a) between H-6 with C-10 ($\delta_C$ 47.2), C-4 ($\delta_C$ 143.0), C-19 ($\delta_C$ 12.8), and C-8 ($\delta_C$ 34.7) just as 2. The relative configurations at C-6 ($\delta_C$ 76.1) and C-10 ($\delta_C$ 47.2) were determined using the NOESY spectrum (Figure S18); the NOESY correlation (Figure 3b) of H-6 with H-10 ($\delta_H$ 1.58; dd, $J = 11.63, 1.30$) and H-8 ($\delta_H$ 1.71; ddd, $J = 14.06, 6.21, 3.58$); simultaneously, H-10 with H-12 ($\delta_H$ 2.33,
m), and H-19 (δH 0.98, s) with H-7α (δH 2.20) showed the same trans-cis-type clerodane skeleton configuration as 2.

To establish the absolute configuration of compounds 2 and 3, specific rotation and comparison of the experimental and calculated ECD curves for the ent isomer (Figure 4) were performed. Specific rotation of 2 ([α]D20 = −12.0) and 3 ([α]D20 = −12.3) were of negative value and similar. The experimental ECD spectrum for compound 2 (blue line, Figure 4) and compound 3 (orange line, Figure 4) showed a positive and negative Cotton effect at 236 nm (Δε = +4.40), 204 nm (Δε = −2.73) for 2, and at 232 nm (Δε = +5.12) and 204 nm (Δε = −3.36) for 3, which fit with the theoretical ECD spectrum simulated for the ent isomer (gray line, ECD theoretical for 2; green line, ECD theoretical for 3; Figure 4). Thus, the absolute configuration for compounds 2–3 was established as 5R, 6S, 8R, 9R, and 10S stereoisomers.

Figure 3. (a) 1H-1H COSY and key HMBC (H—C) correlations of compound 3; (b) key NOESY correlations of compound 3.

Figure 4. Experimental circular dichroism (CD) spectra for compounds 2 and 3, in addition to the calculated CD spectra.
2.2. HPLC Phytochemical Profiling

HPLC profile of the EWE of *C. guatemalensis* was monitored at different wavelengths and the peak heights were evaluated. Maximum peak heights for the extract were obtained at 205, 240, and 254 nm (Figure 5) and were selected as optimum wavelengths to analyze the chromatographic profile. The UV spectra of the peaks showed characteristic bands of flavonoids with features of flavans, flavonols, and terpenes, with their maximum absorptions at 200, 266–280 nm (Band II) for flavans [23] in the first 13 min of the profile; then, maximum absorptions at 230–254 (Band II) and 330–370 nm (Band I) for flavonols [23] between 14 and 20 min, and, finally, absorption maxima of 205, 218, and 240 nm for terpenes [24,25] during 20 to 35 min. Isolated compounds were identified in the chromatogram (Figure 5) by coelution of pure compounds or standards with the extract and comparison of their UV spectra. The profile recorded at 205 nm shows the presence of about eight major peaks released in the retention times, 7.08 min (unidentified), 7.78 min (unidentified), 9.39 min (7), 14.52 min (6), 27.56 min (4), 28.15 min (3), 30.55 min (2), and 32.86 min (1); a general qualitative analysis revealed that the most abundant compound was the junceic acid (1; 32.86 min; 205 nm) followed by the unidentified peak at 7.08 min, 7 (tR = 9.39; 205 nm), 2 (tR = 30.55 min; 205 nm), 4 (tR = 27.56 min; 240 nm), and 6 (tR = 14.52 min; 254 nm).

**Figure 5.** HPLC profile of the EWE of *C. guatemalensis* at 205, 240, and 254 nm and their UV spectra at some peaks at different retention times.

Diterpenes are characteristic components of the *Croton* species and clerodane diterpenes skeletons are the most abundant, being part of 27% of the diterpenes found in *Croton* species [1]. Junceic acid (1) was first isolated from *Solidago juncea* Ait [18] and previ-
ously identified as a major compound in *Croton sarcopetalus* [26] and *Croton arboreus* [27], and it was tested as an anti-inflammatory [28] and phytotoxic [20] agent. Formosin F (4) was previously isolated from *Excoecaria formosana* and analyzed as an antibacterial compound that showed moderate antibacterial activity against two strains of *Helicobacter pylori* [19]. Bartsiifolic acid (5) was previously isolated from *Blakiella bartsiifolia* [20] and *E. formosana* [19]. It was studied as phytotoxic and antimicrobial. In terms of its phytotoxic activity, it restrained seed germination at low concentration and hindered elongation of the shoots [20]; its antibacterial activity was not proven. Some flavonoids were isolated from various *Croton* species [1]; among these are flavans, flavonol aglycones, flavonol glycosides, flavones, etc. Rutin (6) was first described in *Croton menthodorus* [28], subsequently in *Croton caudatus* [29], *Croton sphaerogynus* [30], *Croton polycarpus* [31], *Croton campestris* [6], and finally in *C. urucurana* [9]. This indicates a constant presence of the flavonoid in the genus; therefore, 6 may be useful as a possible phytochemical marker. In addition, this flavonoid meets several requirements to be a chemical marker [32] and its effectiveness as a hypoglycemic agent was demonstrated in several studies [33,34]. For this reason, the rutin (6) quantification method in the EWE of *C. guatemalensis* was validated. Epicatechin (7) was previously described in *Croton lechleri* [35] and *C. urucurana* [36]. This flavanoid was extensively studied as an anti-inflammatory, antioxidant, anti-cancer agent, and as preventing diabetes, cardiovascular diseases, a neuroprotector, and enhancer of muscle performance [37]. Recently, the combination of 7 with rutin (6) (75:25) was tested in the oral administration of alloxan-induced hyperglycemic mice for 28 days, and its chronic hypoglycemic activity yielded similar results to glibenclamide [38]. Quercetin (8) was previously isolated from *Croton sylvaticus* and proved to be a potent inhibitor of acetylcholinesterase [39]. Quercetin (8) was also identified and, in some cases, quantified in *C. sphaerogynus* [30], *C. polycarpus* [31], and *C. urucurana* [9]. This flavonol was extensively studied as an antioxidant, antimicrobial, anti-Alzheimer’s, antiarthritic, anticarcinogenic, and hypoglycemic agent [40]. As far as we know, our current work is the first report of isolation of compounds 1–8 from *C. guatemalensis*, and 2 and 3 are new for the genus.

### 2.3. Quantification of Rutin (6) in *C. guatemalensis* Extract

A comprehensive HPLC method was developed and validated for quantifying rutin (6) according to the International Conference on Harmonization guidelines [41]. Rutin (6) was selected as a chemical marker based on its constant presence in the genus, stability, and pharmacological activity, as previously mentioned. Diterpenes 3, 4, and 5 were not included in the validation process due to their instability. Flavonoids 7 and 8 were neither considered in the validation process due to the lack of a standard for compound 7 and the low concentration in the chromatographic profile in the case of compound 8. The calibration curve showed good linearity within the test range ($R^2 \geq 0.9996$). The LOD and LOQ values were 0.19 and 0.57 µg/mL, respectively. Intraday and interday precision relative standard deviations (RSDs) were no more than 0.79% (Tables 2 and S1, and Figure S23). No significant degradation of 6 was detected in samples investigated over 72 h at room temperature (20 °C), at 37 °C, and at 4 °C, compared with the initial values. The method was linear, precise, and accurate for the quantitative evaluation of the marker. The content of rutin (6) in three batches of *C. guatemalensis* from different years (2014, 2015, and 2019) was investigated and the results are summarized in Table 3. Rutin (6) was identified in all batches with amounts between 0.55 and 0.64 mg/g (mg of 6/g of plant). Previous analyses reported a total of 6.02 mg/g of rutin (6) in leaves of a hydroalcoholic extract of *C. campestris* [6], which suggests a possible higher amount of the flavonoid in the leaves or the use of another solvent, such as methanol, as was shown in other studies [42,43].
Table 2. Validation report of the method for rutin (6) determination in *C. guatemalensis*.

| Rt  | Linear Range (µg/mL) | Calibration Equation | R² | LOD (µg/mL) | LOQ (µg/mL) | Precision Intraday (%RSD) | Precision Interday (%RSD) | Recovery (%mean) |
|-----|----------------------|----------------------|----|-------------|-------------|--------------------------|--------------------------|-----------------|
| 14.52 | 20–250             | Y = 9.29484284x + 17.083753 | 0.9996 | 0.19 | 0.57 | 0.79 | 0.22 | 100.74 |

* a R² correlation coefficient for five data points in the calibration curves (n = 3).

Table 3. Content of rutin (6) in *C. guatemalensis*.

| Batch | %EWE a | Content in mg/g b |
|-------|--------|-------------------|
| 09–2013 | 20.5 | 0.6067 ± 0.0025 |
| 06–2015 | 19.3 | 0.5585 ± 0.0042 |
| 10–2019 | 18.7 | 0.6440 ± 0.0068 |

* a Yield in grams of extract per grams of plant material; b (mg of 6/g of plant material); data are mean ± SD; n = 3.

2.4. Affinity-Directed Fractionation

In 2019, the in vivo hypoglycemic effect of the hydroalcoholic and aqueous extracts of *C. guatemalensis* was demonstrated, and the in vitro inhibition of α-glucosidases was also tested [17]; this assay did not show inhibition of α-glucosidases from rat intestine, thus, ruling out its hypoglycemic action mechanism as an α-glucosidase inhibitor. However, the extract showed greater activity (IC₅₀ = 32 µg/mL) than acarbose (IC₅₀ = 105 µg/mL) against α-glucosidases from *Saccharomyces cerevisiae*. The affinity-directed fractionation assay was implemented to find the metabolites responsible for this activity. EWE of *C. guatemalensis* was subjected to a gel permeation chromatography with a spin column packed with polyacrylamide, previously incubated with the α-glucosidases enzymes. The principle of affinity screening is based on the fact that target enzymes incubated with a complex matrix of natural compounds will retain the most tightly non-covalent binding active molecules from a mixture of closely related compounds [44,45]. The HPLC-MS chromatogram obtained from the affinity screening analysis of the EWE allowed the identifying of some of the ent-clerodane diterpenes observed in the previous fractionation procedures. Figure 6 illustrates the HRESI-MS obtained from these affinity screening assays: the HRESI-MS obtained from the free ligand (329.1670 [M–H]⁻; 27.98–28.09 min) showed compound 4 (Figure 6a; Table 4), (m/z 331.1823 [M–H]⁻; 28.84–28.94 min) showed compounds 3 or 5 (Figure 6b; Table 4), and the free ligand (m/z 315.2467 [M–H]⁻; 30.64–30.79 min) showed compound 1 (Figure 6c; Table 4). Other signals observed in the HPLC-MS spectrum (Figures S24 and S25) are related to other high affinity compounds not observed in the previous fractionation procedures. However, the m/z yields molecular weights of structures with the same base skeleton (clerodane diterpenes) with one or more oxidations, for example: at 25.47–25.65 min the m/z is 363.1715, indicating a possible molecular formula, C₂₁H₃₂O₅, whereas the peak at 27.84–27.98 min with m/z 347.1770 could be C₂₀H₂₈O₅. Further analysis should be performed to confirm these possible structures. New prototypes of modulatory enzymes observed with affinity studies allowed knowing that these diterpenes had a high affinity for the *S. cerevisiae* α-glucosidase enzyme.

The importance of these experiments could be explained by the hypothesis of Kimura [46] that yeast and mammalian α-glucosidases belonged to two different families that differed in their amino acid sequences and their abilities to act on different substrates. The yeast and insect enzymes belong to family I (GH13) and have greater affinity for heterogeneous substrates, such as sucrose or 4-PNGP, whereas α-glucosidases from mammals belong to family II (GH31) and have greater affinity for homogeneous substrates, such as maltose.

In this sense, according to our findings, the inhibition of the Saccharomyces enzymes by the compounds could be more related to an ecological role that enables the plants to defend themselves against insect herbivory or fungal attacks by inhibiting type 1 enzymes.
Table 4. Clerodanes identification with α-glucosidase enzyme and docking studies.

| Compound | Formula a | ESI-MS [M–H] b | ESI-MS [M + H] b | MAL12 | MGAM |
|----------|-----------|----------------|-----------------|-------|-------|
|          |           |                |                 | Theoretical Ki | Hydrogen Bond | Theoretical Ki | Hydrogen Bond |
| 1        | C_{20}H_{25}O_{3} (316) | 315.2467 |  | 7.12 μM | His279, Arg312 | 3.02 μM | Gln1372, Arg1377 |
| 2        | C_{22}H_{33}O_{5} (374) | - | - | 17.1 μM | His279, Arg312 | 6.31 μM | Gln1372, Arg1377 |
| 3        | C_{20}H_{25}O_{4} (332) | 331.1823 | 333.2444 | 13 μM | Arg312 | 5.09 μM | Gln1372, Arg1377 |
| 4        | C_{20}H_{25}O_{4} (330) | 329.1670 | - | 6.73 μM | His279, Arg312 | 1.95 μM | Gln1372, Arg1377 |
| 5        | C_{20}H_{25}O_{4} (332) | 331.1823 | 333.2444 | 4.14 μM | His279, Arg312 | 2.4 μM | Tyr1251, Arg1377 |
| Acarbose c | C_{20}H_{25}NO_{16} (645) | - | 646 | 51.4 nM | His279, Gln322, Glu304, Arg312 | 35.7 nM | Gln1361, Gly1588 |

- a Molecular weight (Da).
- b Observed in affinity studies.
- c Positive control substance.

2.5. Molecular Docking

Compounds 1–5 and acarbose (control) were constructed in 3D models and molecular docking studies between ligands (acarbose and compounds 1–5) and the amino acid sequence of α-glucosidase from S. cerevisiae (MAL12) and human maltase-glucoamylase (MGAM-C) by AutoDock 4.2 software were performed to improve our understanding of the interaction of the high affinity compounds 1–5 inside the catalytic sites of MAL12 and MGAM-C, which were selected as the template for molecular modeling to establish...
a comparison between the resulting affinity-directed fractionation assay and the theoretical inhibition constant ($K_i$) obtained from in silico studies. To refine the results, the best conformations observed in the preliminary analysis were docked into a smaller area of the catalytic domain. Data are shown in Table 4. Acarbose fits well in the catalytic pocket of the analyzed enzymes and showed hydrogen-bonding interactions with the amino acid residues HIS279 (2.08 Å), GLN322 (2.00 Å), and ARG312 (2.15 Å) with MAL12, whereas the binding modes inside the catalytic site of MGAM-C corresponded to TYR1251 (1.93 Å), GLN1372 (1.75 Å), ARG1377 (2.11 Å), GLN1561 (2.07 Å), and GLY1588 (2.17 Å). Compounds 1–5 fit well in the catalytic pocket with MAL12 and showed hydrogen-bonding interactions with the amino acid residues HIS279 and ARG312, and preserved catalytic residues around TYR1251 in MGAM, which is involved in the catalytic substrate specificity of this protein [47]. Compounds 4 and 5 have the lowest $K_i$ values of both analyzed enzymes (Table 4). These results plus the results of affinity studies with $\alpha$-glucosidase indicate that the best conformation for enzyme inhibition is that of compound 5 (Figure 7).

![Figure 7. Docking results of the enzyme binding conformation of compound 5 with MAL12, three hydrogen bonds formed with catalytic residues SER156, HIS279, and ARG312.](image)

A secondary study was carried out in the catalytic site, using acarbose as a control and the best conformation of each compound 1–5 of the refine study. This allowed knowing the pharmacophore of compounds 1–5. Figure 8 shows the minimized structure of the $\alpha$-glucosidase complexed with active compounds 1–5 in the hypothesized binding mode. The furane group at C-13 of all compounds forms a hydrogen bond with the NH of the catalytic residue HIS279, inducing a greater steric impediment at the surface of the catalytic pocket.
we used similar extracts to those previously tested \[17\], some of the compounds isolated using ceric sulfate (10\%) solution in H\(_2\)SO\(_4\) (Merck Mexico) or Sephadex LH-20 (Sigma-Aldrich Chemical). Thin-layer chromatography analyses were carried out on silica gel 60 F\(_{254}\) plates (Macherey-Nagel, Düren, Germany) using ceric sulfate (10\%) solution in H\(_2\)SO\(_4\) as color reagent. NMR spectra including \(^1\)H, \(^13\)C, DEPT, HSQC, HMBC, COSY, NOESY, and TOCSY were recorded in a Varian Inova 400 MHz spectrometer (Varian, Inc., Palo Alto, CA, USA) at 400 \(\text{MHz}\) and 100 \(\text{MHz}\) using TMS as internal standard. High-resolution ESI-MS was measured in a coupled liquid chromatography system with 70–230 mesh (Merck Mexico) or Sephadex LH-20 (Sigma-Aldrich Chemical). Thin-layer chromatography analyses were carried out on silica gel 60 F\(_{254}\) plates (Macherey-Nagel, Düren, Germany) using ceric sulfate (10\%) solution in H\(_2\)SO\(_4\) as color reagent. NMR spectra including \(^1\)H, \(^13\)C, DEPT, HSQC, HMBC, COSY, NOESY, and TOCSY were recorded in a Varian Inova 400 MHz spectrometer (Varian, Inc., Palo Alto, CA, USA) at 400 \(\text{MHz}\) and 100 \(\text{MHz}\) using TMS as internal standard. High-resolution ESI-MS was measured in a coupled liquid chromatography system with 

**Figure 8.** Pharmacophore docking results show the minimized structure of MAL12 with the active compounds 1–5, the furane group forms a hydrogen bond with the NH of the catalytic residue HIS279.

### 3. Conclusions

In this study, eight compounds were isolated from de bark of *C. guatemalensis*, and the absolute configuration of two unreported *ent*-clerodane diterpenoids (2 and 3) were established by ECD spectrum. Quantification of the flavonoid rutin (6) was validated and analysis of three different batches indicated very similar amounts of rutin (6) content in each of them.

The approach for affinity-directed fractionation was applied at various stages during the isolation and purification processes to speed the identification of new \(\alpha\)-glucosidase inhibitors, which could have an impact in the microscale separation and dereplication of active natural products, as demonstrated here for the clerodanes from *C. guatemalensis*. The present study provides insights into the phytochemical composition of the hydroalcoholic extract of *C. guatemalensis* and reveals new prototypes of enzyme modulators through affinity studies. As previously mentioned, these findings could be related to an ecological role that enables the plant to defend themselves against herbivory insects or fungal attacks by inhibiting enzymes of family I, according to Kimura [46]. Because, in the present work, we used similar extracts to those previously tested [17], some of the compounds isolated herein could be involved in the previously observed hypoglycemic activity. However, more experiments are needed to confirm this.

### 4. Materials and Methods

#### 4.1. General Experimental Procedure

Analytical and preparative HPLC analyses were performed in an Agilent 1260 Infinity system equipped with a G1311B quaternary pump, G1367E autosampler, G1315C DAD VL+, and controlled by Agilent ChemStation software (Agilent Technologies, Inc., Santa Clara, CA, USA). For analytical and semipreparative HPLC, a Luna Omega Polar C\(_18\), 50 × 2.1 mm id., 1.6 \(\mu\)m column (Phenomenex, Inc., Torrance, CA, USA) was used. Rutin and quercetin standards (>94\% HPLC) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Column chromatography (CC) was carried out on silica gel (70–230 mesh, Merck Mexico) or Sephadex LH-20 (Sigma-Aldrich Chemical). Thin-layer chromatography analyses were carried out on silica gel 60 F\(_{254}\) plates (Macherey-Nagel, Düren, Germany) using ceric sulfate (10\%) solution in H\(_2\)SO\(_4\) as color reagent. NMR spectra including \(^1\)H, \(^13\)C, DEPT, HSQC, HMBC, COSY, NOESY, and TOCSY were recorded in a Varian Inova
spectrometer (Varian, Inc., Palo Alto, CA, USA) at 400 ($^1$H) and 95 MHz ($^{13}$C) or Bruker DMX500 spectrometer (Bruker Nano GmbH, Berlin, Germany) operating at 500 MHz ($^1$H) or 125 MHz ($^{13}$C) NMR; chemical shifts were recorded as δ values. High-resolution ESI-MS was measured in a coupled liquid chromatography system with single quadruple mass spectrometry and time of flight (HPLC-EM-SQ-TOF Model G6530BA, Agilent Technologies, Inc.). HR-MS data were obtained using a Jeol, AccuTOF JMS-T100LC mass spectrometer (HR-DART-MS) (JEOL USA, Peabody, MA, USA). ECD data were obtained using a JASCO, J-1500 CD spectrometer (JASCO, Oklahoma City, OK, USA). IR data were obtained using a FT-IR Bruker Tensor 27 spectrometer.

4.2. Plant Material and Extracts

_Croton guatemalensis_ was collected by Dr. Carola Cruz, based on previous ethnobotanical studies (Cruz, 2011), at the Department of Chimaltenango, Guatemala, in 2019. Ethanol–water extract (EWE) was made by heating 20 g of the dry plant material with a mixture of ethanol:water (1:1; 500 mL) during 2 h, followed by filtration and concentration under reduced pressure to remove ethanol in a rotary vacuum evaporator (Büchi Labortechnick, AG, Flawil, Switzerland) at 40 °C. Finally, it underwent lyophilization to yield 4.058 g of EWE. The extract was stored at 4 °C for HPLC analysis.

For phytochemical analysis, the dried and ground material (60 g) of _C. guatemalensis_ was extracted with a mixture of ethanol:water (1500 mL) during two hours and then filtered and extracted with CH$_2$Cl$_2$ (3 × 1500), followed by extraction with ethyl acetate (3 × 1500), to yield 3.7525 g of CH$_2$Cl$_2$-soluble fraction (DSF), 754 mg of EtOAc-soluble fraction (ESF), and 5.2820 g of H$_2$O-soluble fraction (WSF).

4.3. Isolation Compounds

DSF (3.70 g) was partitioned by column chromatography (CC) on 95 g of silica gel (70–230 mesh, Merck Mexico) using mixtures of n-hexane/EtOAc/MeOH as eluent, starting with n-hexane 100%, increasing the polarity with EtOAc until 100%, and subsequently with MeOH, obtaining 164 collections of 50 mL that were gathered according to their chromatographic profile analyzed by TLC. This process led to 35 primary fractions (DSF1-DSF35). Fraction DSF1 (1.16 g) was obtained as the pure compound 1; preparative TLC of fractions DSF6 (122.3 mg; CH$_2$Cl$_2$:MeOH, 97:3; 2.0 mm), DSF11 (58.3 mg; n-hexane:EtOAc, 75:25, 1.0 mm), and DSF13 (62.1 mg; n-hexane:EtOAc:Me$_2$CO; 50:45:5; 1 mm) yielded 64.0 mg of 2, 16.0 mg of 3, and 16.6 mg of 4; 54.5 mg of DSF14 was subjected to TLC (CH$_2$Cl$_2$:MeOH; 97:3) to obtain 10.5 mg of 5, and 7.5 mg of 4.

ESF (692 mg) was subjected to Sephadex LH-20 using MeOH 100% as eluent, and this process led to 20 subfractions (ESF1-ESF20); ESF8 (15.2 mg) was analyzed by HPLC to be compared with the UV spectrum of a standard of rutin (6) (>94% HPLC; Sigma-Aldrich) and was corroborated by its mass spectrum (ESI-MS). ESF10 (37.0 mg) was resolved by semi-preparative HPLC (Nucleosil 250 × 10 mm i.d., 5 μm, C18 Macherey-Nagel), using a mixture of 15:85 MeCN:H$_2$O as mobile phase during 15 min (2.0 mL/min; 280 nm UV-det.) to obtain 8.2 mg of 7 (Rt = 12.5 min).

MeOH (200 mL) was added to the WSF to obtain 672 mg soluble in methanol, which was subjected to Sephadex LH-20 using MeOH 100% as eluent. This process led to 17 subfractions (WSF1-WSF17); WSF16 (9.1 mg) was isolated as the pure compound 8 and analyzed by HPLC to be compared with the UV spectrum of a quercetin standard (>94% HPLC; Sigma-Aldrich), which was confirmed.

4.3.1. 6(s)-Acetoxy-15,16-diepoxy-ent-cleroda-3,13(16),14-trien-20-oic Acid (Crotoguatenolic Acid A; 2)

White powder; [α]$_D^{20}$-12.0 (c 0.001 MeOH); UV (MeOH) $\lambda_{max}$ (log ε) 210 (0.972) nm; ECD (MeOH) $\lambda_{max}$ (Act) 204 (−2.73), 236 (+4.40); IR $\nu_{max}$ 3380 (OH), 1714 (COOH), 1693 (C=O), 1408 (C=C), 1358 (C=C), 1372 (C=C) cm$^{-1}$; $^1$H (CDCl$_3$, 400 MHz), and $^{13}$C NMR
4.3.2. 6(s)-Hydroxy-15,16-diepoxy-ent-cleroda-3,13(16),14-trien-20-oic Acid
(Crotoguatenic Acid B; 3)

White powder; [α]D20 = −12.3 (c 0.001 MeOH); UV (MeOH) λmax (log ε) 234 (1.34); ECD (MeOH) (Δε) 204 (−0.3.36), 232 (+5.12); IR νmax 3399 (OH), 1695 (C=O), 1450 (C=C), 1376 (C=C) cm−1; 1H (CDCl3, 400 MHz) and 13C NMR (CDCl3, 150 MHz), see Table 1; HRESIMS m/z 333.20515 [M + H]+ (calcd. for C20H29O4, 333.20658).

4.4. HPLC Analysis

High performance liquid chromatography (HPLC) was developed using an Agilent 1260 HPLC instrument equipped with an Agilent G1315C UV diode array detector (DAD). Chromatographic profile elaboration was performed using a Phenomenex (Luna Omega Polar C18, 50 × 2.1 mm id., 1.6 µm) reverse phase column. Elution was carried out at a flow rate of 0.35 mL/min with water as solvent A, containing 0.1% formic acid and acetonitrile (MeCN) as solvent B, starting with a gradient elution of 99:1 (A:B), 80:20 (A:B) at 14 min, 50:50 (A:B) at 14–26 min, 70:30 (A:B) at 26–34 min, 20:80 (A:B) at 34–35 min, and 99:1 (A:B) at 35–38 min. The column temperature was kept at 35 °C. System control, data collection, and processing were accomplished using the OpenLAB LC 1260 chromatography software. Working solutions of samples (EWE, fractions, and isolated compounds) of C. guatemalensis were prepared by dissolving 10.0 mg of EWE in 1 mL of a mixture of MeCN:H2O (1:1) or 1 mg of the compound in 1 mL of the required solvent according to its solubility (EtOH, MeOH, MeCN, or H2O), which were injected (2 µL) using an autosampler. For UV detection, the wavelength program was set at an acquisition of λ 205, 240, 254, 280, and 365 nm.

4.5. HPLC Method Validation

The method was validated according to the ICH guidelines for specificity, linearity, accuracy, precision, LOQ, and LOD [41]. Specificity was checked using the extract and a rutin (6) standard. Linearity of the method was evaluated by inspection of a rutin (6) standard solution at a concentration range of 20 to 250 µg/mL. A calibration line was made, and the least square line and correlation coefficient were calculated. Accuracy was evaluated by means of recovery assays carried out by adding known amounts of the standards of 6 to the sample at three different levels of the initial concentration of the sample. Average recoveries were calculated by the Equation (1).

\[
\text{Recovery (\%)} = \left(\frac{\text{amount found} - \text{original amount}}{\text{amount spiked}}\right) \times 100
\]  

Precision was evaluated by repeatability using six replicates at 100% of the test concentration. Stability was tested by analyzing the sample solution at different time points (0, 24, 48, and 72 h). LOD and LOQ were quantified based on the standard deviation (σ) of the response and the slope (S) calculated by the equations 2 and 3, respectively.

\[
\text{LOD} = \frac{3.3\sigma}{S}
\]

\[
\text{LOQ} = \frac{10\sigma}{S}
\]

4.6. Affinity-Directed Fractionation

Gel permeation chromatography was performed with a spin column (BioRad Laboratories, Hercules, CA, USA) packed with polyacrylamide, 1 cm high, 100 µL swollen). The gel and samples were prepared in a solution of 0.1 M sodium phosphate buffer (pH 6.8) [45]. Aliquots (10 µL, in triplicates) of the extract (200 µg/mL) and acarbose (therapeutic control) were independently incubated for 5 min with 20 µL of the enzyme stock solution.
with geometric optimization for all ligands, utilizing a semiempirical method (PM3). The www.mdpi.com/article/10.3390/plants11223159/s1. Figure S1: The (R (0.9 units/mL of yeast α-glucosidase in 100 μM of buffer solution). Upon loading the test samples at the top of the spin exclusion column, the mixtures were eluted by centrifugation at RCF 42,985 g for 4 min; then, the eluate, corresponding to the solvent front and containing the α-glucosidase-acarbose complex, was collected and a denaturing solution (10 μL) of 3% glacial acetic acid in acetonitrile:water (1:1, v:v) was added and mixed with a vortex mixer. The solution was vacuum-dried and reconstituted with acetonitrile and analyzed by a coupled liquid chromatography system with single quadruple mass spectrometry and time of flight (HPLC-EM-SQ-TOF). Chromatographic profile elaboration was performed using a Phenomenex (Kinetex C18, 50 × 2.1 mm id., 2.6 μm) reverse phase column; the same flow gradient conditions mentioned above (item 4.4) were used. ESI mass spectra after the SEC/ESI-MS protocol for the acetonitrile and the enzyme functioned as background signals for the spectrum of the samples of interest.

4.7. Molecular Docking

Docking was carried out with the AutoDock 4.2 software (The Scripps Research Institute, La Jolla, CA, USA) using the default parameters. The molecular docking was performed with a model built by homology with Bacillus cereus α-glucosidase (1UOK.PDB) for the amino acid sequence of MAL12 from S. cerevisiae, which was retrieved from the UniProt protein resource data bank (accession code P5334) with preserved catalytic residues His111, Asp205, Glu276, His348, and Asp349 [48]. All files were prepared by adding polar hydrogen atoms and merged non-polar hydrogens to the enzyme structures and computing Gasteiger charges for the molecular model of analyzed compounds (1–5) as previously described for acarbose [48]. The entire system was subjected to a surface scanning and refined docking.

4.8. Computational Details

The Spartan’14 software was implemented to calculate the energy-minimized form with geometric optimization for all ligands, utilizing a semiempirical method (PM3). The resulting conformers were filtered and checked for redundancy. All conformers were minimized using a DFT force field at the B3LYP/DGDZVP level of theory employing Gaussian 09 software. The conformers were optimized, and thermochemical properties, IR, and vibrational analyses were obtained at the same level of theory. The TD-SCF with the default solvent model was used to perform the theoretical circular dichroism (TCD) calculations of the major conformers in the MeOH solution, using a B3LYP/DGDZVP force field. The calculated excitation energy (nm) and rotatory strength (R) in dipole velocity calculations of the major conformers in the MeOH solution, using a B3LYP/DGDZVP force field. The calculated excitation energy (nm) and rotatory strength (R) in dipole velocity (R_{vel}) form was simulated into a TCD curve using the Harada–Nakanishi equation, as implemented in the SpecDis 1.71 software [49].

**Supplementary Materials**: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/plants11223159/s1. Figure S1: The {superscript}1H NMR spectrum of 2 in CDCl{subscript}3 (500 MHz); Figure S2: The {superscript}13C NMR spectrum of 2 in CDCl{subscript}3 (125 MHz); Figure S3: The DEPT spectrum of 2 in CDCl{subscript}3 (125 MHz); Figure S4: The HSQC spectrum of 2 in CDCl{subscript}3; Figure S5: The {superscript}1H-{superscript}1H COSY spectrum of 2 in CDCl{subscript}3; Figure S6: The HMBC spectrum of 2 in CDCl{subscript}3; Figure S7: The NOESY spectrum of 2 in CDCl{subscript}3; Figure S8: The TOCSY spectrum of 2 in CDCl{subscript}3; Figure S9: The ESI-MS spectrum of compound 2; Figure S10: The UV spectrum of compound 2; Figure S11: The IR spectrum of compound 2; Figure S12: The {superscript}1H NMR spectrum of 3 in CDCl{subscript}3 (500 MHz); Figure S13: The {superscript}13C NMR spectrum of 3 in CDCl{subscript}3 (125 MHz); Figure S14: The DEPT spectrum of 3 in CDCl{subscript}3 (125 MHz); Figure S15: The HSQC spectrum of 3 in CDCl{subscript}3; Figure S16: The {superscript}1H-{superscript}1H COSY spectrum of 3 in CDCl{subscript}3; Figure S17: The HMBC spectrum of 3 in CDCl{subscript}3; Figure S18: The NOESY spectrum of 3 in CDCl{subscript}3; Figure S19: The TOCSY spectrum of 3 in CDCl{subscript}3; Figure S20: The HRESIMS spectrum of compound 3; Figure S21: The UV spectrum of compound 3; Figure S22: The IR spectrum of compound 3; Figure S23: Calibration curve of rutin (6); Figure S24: HPLC-ESIMS spectrum obtained from the affinity screening analysis of the EWE soluble extract with a-glucosidase, positive mode; Figure S25: HPLC-ESIMS spectrum obtained from the affinity screening analysis of the EWE soluble extract with a-glucosidase, negative mode; Table S1: Standard calibration curve of rutin (6).
Author Contributions: Envisioned the study, A.A.-C., Conceptualization, S.M.E.-R., A.A.-C. and D.G.R.-R.; methodology, S.M.E.-R. and D.G.R.-R.; software, D.G.R.-R.; validation, S.M.E.-R., D.G.R.-R. and A.A.-C.; formal analysis, S.M.E.-R., D.G.R.-R., A.A.-C. and R.A.-E.; investigation, S.M.E.-R. and D.G.R.-R.; resources, A.A.-C. and R.A.-E.; supervision, A.A.-C.; project administration, A.A.-C. and R.A.-E.; funding acquisition, A.A.-C. and R.A.-E. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the Universidad Nacional Autónoma de México of the Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (UNAM-PAPIIT), by the projects No. IN213222 and IN215823.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data in this study can be found in the manuscript or in the Supplementary Materials.

Acknowledgments: We thank Carola Cruz (Universidad de San Carlos Guatemala, RIP) for the plant material, Everardo Tapia Mendoza (Instituto de Química, UNAM) for support during the recording of mass spectra, Elizabeth Huerta Salazar (Instituto de Química, UNAM) for support during the recording of RMN spectra and Adriana Romo Pérez (Instituto de Química, UNAM) for support during the recording of ECD, UV, and IR spectrum. D.G.R.-R. is grateful to CONACYT for the postdoctoral scholarship (CVU 205045).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Xu, W.H.; Liu, W.Y.; Liang, Q. Chemical Constituents from Croton Species and Their Biological Activities. *Molecules* **2018**, *23*, 2333. [CrossRef] [PubMed]
2. Salatino, A.; Faria Salatino, M.L.; Negri, G. Traditional Uses, Chemistry and Pharmacology of Croton Species (Euphorbiaceae). *J. Braz. Chem. Soc.* **2007**, *18*, 11–33. [CrossRef]
3. Cruz, E.C.; Andrade-Cetto, A. Ethnopharmacological Field Study of the Plants Used to Treat Type 2 Diabetes among the Cakchiquels in Guatemala. *J. Ethnopharmacol.* **2015**, *159*, 238–244. [CrossRef] [PubMed]
4. Okokon, J.E.; Nwafor, P.A. Antiplasmodial Activity of Root Extract and Fractions of *Croton gratissimus* Kunth Leaves. *Nat. Prod. Commun.* **2012**, *7*, 1233–1236. [CrossRef]
5. Júnior, S.F.P.; Conserva, L.M.; Filho, J.M.B. Clerodane Diterpenes from *Croton* Species: Distribution and a Compilation of Their 13C NMR Spectral Data. *Nat. Prod. Commun.* **2006**, *1*, 1934–1940. [CrossRef]
6. Gomes, K.K.; MacEdo, G.E.; Rodrigues, N.R.; Ziech, C.C.; Martins, I.K.; Rodrigues, J.F.; De Brum Vieira, P.; Boligon, A.A.; De Brito Junior, F.E.; De Menezes, I.R.A.; et al. *Croton campestris* A. St.-Hill Methanolic Fraction in a Chlorpyrifos-Induced Toxicity Model in *Drosophila melanogaster*: Protective Role of Gallic Acid. *Oxid. Med. Cell Longev.* **2020**, *2020*, 3960170. [CrossRef]
7. Ortiz, A.P.; Puebla, P.; Guerrero, M.F. Vascular Interactions of *Croton Schiedeana* Major Flavonoids in Isolated Aortic Rings from Wistar Rats. *Vitae* **2021**, *28*, 1–14. [CrossRef]
8. Cheila, C.B.; dos Anjos, G.L.; Nobrega, R.S.A.; da Magaton, A.; de Miranda, F.M.; de Dias, F. Greener Ultrasound-Assisted Extraction of Bioactive Phenolic Compounds in *Croton heliotropifolius* Kunth Leaves. *Microchem. J.* **2020**, *159*, 105525. [CrossRef] [PubMed]
9. Oliana, J.; Ferreira, M.J.P.; Salatino, A.; Salatino, M.L.F. Leaf Flavonoids from Croton Urucurana and *C. floribundus* (Euphorbiaceae). *Biochem. Syst. Ecol.* **2021**, *94*, 104217. [CrossRef]
10. Turiel, N.A.; Ribeiro, A.F.; Carvalho, E.E.N.; Domingos, V.D.; Lucas, F.C.A.; Carreira, L.M.M.; Andrade, E.H.A.; Maia, J.G.S. Essential Oils Composition of *Croton Species* from the Amazon. *Nat. Prod. Commun.* **2013**, *8*, 1471–1772. [CrossRef]
11. Morais, S.M.; Coelho, D.S.; Silva, A.A.S.; de Moraes Filho, M.O.; Teixeira, M.J.; Campello, C.C.; Bonilla, O.H.; de Paula, V.F.; Vila-Nova, N.S. Essential Oils from *Croton Species*: Chemical Composition, in Vitro and in Silico Antileishmanial Evaluation, Antioxidant and Cytotoxicity Activities. *J. Braz. Chem. Soc.* **2019**, *30*, 2404–2412. [CrossRef]
12. Castro, K.N.d.C.; Chagas, A.C.d.S.; Costa-Júnior, L.M.; Canuto, K.M.; Brito, E.S.D.; Rodrigues, T.H.S.; de Andrade, I.M. Acaricidal Potential of Volatile Oils from *Croton Species* on *Rhipicephalus Microplus*. *Rev. Bras. Farmacogn.* **2019**, *29*, 811–815. [CrossRef]
13. Carlos Dantas da Cruz, R.; da Silva Carvalho, K.; Justino Oliveira Costa, R.; Alexandre da Silva, P.; ucia da Cunha Silva, S.L.; Andrade Gualberto, S.; Buarque de Gusm, N.; Antonio de Souza, I. Phytochemical and Toxicological Evaluation of a Blend of Essential Oils of *Croton Species* on Aedes Aegypti and Mus Musculus. *S. Afr. J. Bot.* **2020**, *132*, 188–195. [CrossRef]
14. Sadgrove, N.J.; Madeley, L.G.; Van Wyk, B.E. Volatiles from *Croton* (Euphorbiaceae), Including New Diterpenes in Essential Oil from *Croton gratissimus*. *Helyon* **2019**, *5*, e02677. [CrossRef] [PubMed]
15. Franssen, F.F.J.; Smeijsters, L.J.J.W.; Berger, I.; Medinilla Aldana, B.E. In Vivo and in Vitro Antiplasmodial Activities of Some Plants Traditionally Used in Guatemala against Malaria. *Antimicrob. Agents Chemother.* **1997**, *41*, 1500–1503. [CrossRef]
16. José Del Carmen, R.O.; Willam, H.M.J.; Del Carmen, G.M.A.; Nataly, J.G.; Stefany, C.O.S.; Anahi, C.A.; Domingo, P.T.J.; Leonardo, G.P.; De La Mora Miguel, P. Antinociceptive Effect of Aqueous Extracts from the Bark of Croton guatemalensis Lotsy in Mice. *Res. Pharm. Sci.* **2016**, *11*, 15–22.

17. Andrade-Cetto, A.; Cruz, E.C.; Cabello-Hernández, C.A.; Cárdenas-Vázquez, R. Hypoglycemic Activity of Medicinal Plants Used among the Cakchiquels in Guatemala for the Treatment of Type 2 Diabetes. *Evid.-Based Complement. Altern. Med.* **2019**, *2019*, 2168603. [CrossRef]

18. Henderson, M.S.; Murray, R.D.H.; McCrindle, R.; McMaster, D. Constituents of Solidago Species. Part III. The Constitution of Diterpenes from Solidago juncea Ait. *Can. J. Chem.* **1931**, *51*, 1322–1331. [CrossRef]

19. Lin, B.D.; Zhou, B.; Dong, L.; Wu, Y.; Yue, J.M. Formosins A–F: Diterpenoids with Anti-Microbial Activities from *Excoecaria Formosana*. *Nat. Prod. Bioprospect.* **2016**, *6*, 57–61. [CrossRef]

20. Rodriguez-Hernández, D.; Oliveros-Bastidas, A.; Alonso-Amelot, M.E.; Calcagno-Pissarelli, M.P. Diterpene Foliar Exudates of *Blakiea Bartisiafolia* and Phytotoxicity of Clerodanes. *Nat. Prod. Commun.* **2014**, *9*, 1407–1412. [CrossRef]

21. Seto, R.; Nakamura, H.; Nanjo, F.; Hará, Y. Preparation of Epimers of Tea Catechins by Heat Treatment. *Biosci. Biotechnol. Biochem.* **1997**, *61*, 1434–1439. [CrossRef]

22. Li, R.; Morris-Natschke, S.L.; Lee, K.H. Clerodane Diterpenes: Sources, Structures, and Biological Activities. *Nat. Prod. Rep.* **2016**, *33*, 1166–1226. [CrossRef] [PubMed]

23. Vihakas, M. Flavonoids and Other Phenolic Compounds: Characterization and Interactions with Lepidopteran and Sawfly Larvae; Birth Defects Orig. Art. Ser; Turun yliopisto: Turku, Finland, 1975; Volume 11, ISBN 9789512959051.

24. Wolfender, J.L. HPLC in Natural Product Analysis: The Detection Issue. *Planta Med.* **1991**, *57*, 1434–1439. [CrossRef]

25. O’Connor, R.T.; Goldblatt, L.A. Correlation of Ultraviolet and Infrared Spectra of Terpene Hydrocarbons. *Anal. Chem.* **1954**, *26*, 1726–1737. [CrossRef]

26. De Heluani, C.S.; Catalán, C.A.N.; Hernández, L.R.; Burgueño-Tapia, E.; Joseph-Nathan, P. 13C NMR Assignments and Conformational Evaluation of Diterpenes from *Croton sarcopetala* Muell. *Magn. Reson. Chem.* **1998**, *36*, 947–950. [CrossRef]

27. Aguilar-Guadarrama, A.B.; Rios, M.Y. Three New Sesquiterpenes from *Croton arboresus*. *J. Nat. Prod.* **2004**, *67*, 914–917. [CrossRef]

28. Capasso, A.; Piacente, S.; De Tommasi, N.; Ragucci, M.; Pizza, C. Constituents of *Croton menthodorus* and Their Effects on Electrically Induced Contractions of the Guinea-Pig Isolated Ileum. *Phytther. Res.* **2000**, *14*, 156–159. [CrossRef]

29. Zou, G.A.; Su, Z.H.; Zhang, H.W.; Wang, Y.; Yang, J.S.; Zou, Z.M. Flavonoids from the Stems of *Croton caudatus* Geisel. *Var. Tomentosum* *Hook. Molecules* **2010**, *15*, 1097–1102. [CrossRef]

30. Dos Santos, K.P.; Motta, L.B.; Santos, D.Y.A.C.; Salatino, M.L.F.; Salatino, A.; Ferreira, M.J.P.; Lago, J.H.G.; Ruiz, A.L.G.; De Carvalho, J.E.; Furlan, C.M. Antiproliferative Activity of Flavonoids from *Croton sphaerogynus* Baill. (Euphorbiaceae). *Biomed. Res. Int.* **2015**, *2015*, 212809. [CrossRef]

31. Aponte-Buitrago, R.; Mayorga-Wandurraga, H.; Moreno-Murillo, B. Flavonols and Sesquiterpenes from Outer Bark and Leaves of *Croton Polycarpus* Benth. (Euphorbiaceae). *Blacipna* **2017**, *16*, 471–485.

32. Li, S.; Han, Q.; Qiao, C.; Song, J.; Xu, H. Chinese Medicine Chemical Markers for the Quality Control of Herbal Medicines: An Overview. *Chin. Med. 2008*, *3*, 7. [PubMed]

33. Yen, F.S.; Qin, C.S.; Tan, S.; Xuan, S.; Ying, P.J.; Le, H.Y.; Darmaranar, T.; Gunasekaran, B.; Salvamani, S. Hypoglycemic Effects of Plant Flavonoids: A Review. *Evid.-Based Complement. Altern. Med.* **2021**, *2021*, 2057333. [CrossRef]

34. Escandón-Rivera, S.M.; Mata, R.; Andrade-Cetto, A. Molecules Isolated from Mexican Hypoglycemic Plants: A Review. *Molecules* **2020**, *25*, 4145. [CrossRef] [PubMed]

35. Cai, Y.; Evans, J.F.; Roberts, M.F.; Phillipson, J.D.; Zenk, M.H.; Gleba, Y.Y. Polyphenolic Compounds from *Croton lechleri*. *Phytomedicine* **1991**, *30*, 2033–2040. [CrossRef]

36. Cordeiro, K.W.; Felipe, J.L.; Malange, K.F.; Do Prado, P.R.; De Oliveira Figueiredo, P.; Garcez, W.S.; Toffoli-Kadri, M.C. Anti-Inflammatory and Antinociceptive Activities of *Croton urucurana* Baillon Bark. *J. Ethnopharmacol.* **2016**, *183*, 128–135. [CrossRef] [PubMed]

37. Qu, Z.; Liu, A.; Li, P.; Liu, C.; Xiao, W.; Huang, J.; Liu, Z.; Zhang, S. Advances in Physiological Functions and Mechanisms of (-)-Epicatechin. *Crit. Rev. Food Sci. Nutr.* **2021**, *61*, 211–233. [CrossRef] [PubMed]

38. Mechchate, H.; Es-safi, I.; Haddad, H.; Bekkari, H.; Grafow, A.; Bousta, D. Combination of Catechin, Epicatechin, and Rutin: Optimization of a Novel Complete Antidiabetic Formulation Using a Mixture Design Approach. *J. Nutr. Biochem.* **2021**, *88*, 108520. [CrossRef]

39. Aderogba, M.A.; Ndhlala, A.R.; Van Staden, J. Acetylcholinesterase Inhibitors from *Croton Sylvaticus* Ethyl Acetate Leaf Extract and Their Mutagenic Effects. *Nat. Prod. Commun.* **2013**, *8*, 795–798. [CrossRef]

40. Salehi, B.; Machin, L.; Monzote, L.; Sharifi-Rad, J.; Ezzat, S.M.; Salem, M.A.; Merghany, R.M.; El Mahdy, N.M.; Kılıç, C.S.; Sytar, O.; et al. Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health. *ACS Omega* **2020**, *5*, 11849–11872. [CrossRef]

41. ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. *ICH Harmon. Tripart. Guidel.* **2005**, *1–13*. [CrossRef]

42. Salgado-Garciglia, R.; Hernández-García, A.; Montiel-Montoya, J.; Valdez-Morales, M.; López-Valdez, L.G.; Herrera-Cabrera, B.E.; Zaragoza-Martínez, F.; Lucho Constantino, G.G.; Barrales-cureño, H.J. Flavonoids Quantification in *Acer Negundo* L., Extracts by Hplc Analysis. *Agro Product.* **2021**, *II*, 1–8. [CrossRef]

43. Saraf, A.; Sankhala, S. Simultaneous Determination of Rutin and Quercetin in Different Parts of Tecomella Undulata (Seem): An Endangered Medicinal Plant. *Int. J. Pharmacogn. Phytochem. Res.* **2014**, *6*, 434–439.
44. Fan, M.; Chen, G.; Sun, B.; Wu, J.; Li, N.; Sarker, S.D.; Nahar, L.; Guo, M. Screening for Natural Inhibitors of Human Topoisomerase from Medicinal Plants with Bio-Affinity Ultrafiltration and LC–MS. *Phytochem. Rev.* 2020, 19, 1231–1261, ISBN 0123456789. [CrossRef]

45. Rosas-Ramírez, D.; Pereda-Miranda, R.; Escandón-Rivera, S.; Arreguin-Espinosa, R. Identification of α-Glucosidase Inhibitors from Ipomoea Alba by Affinity-Directed Fractionation-Mass Spectrometry. *Rev. Bras. Farmacogn.* 2020, 30, 336–345. [CrossRef]

46. Kimura, A.; Lee, J.H.; Lee, I.S.; Lee, H.S.; Park, K.H.; Chiba, S.; Kim, D. Two Potent Competitive Inhibitors Discriminating α-Glucosidase Family I from Family II. *Carbohydr. Res.* 2004, 339, 1035–1040. [CrossRef] [PubMed]

47. Ren, L.; Qin, X.; Cao, X.; Wang, L.; Bai, F.; Bai, G.; Shen, Y. Structural Insight into Substrate Specificity of Human Intestinal Maltase-Glucoamylase. *Protein Cell* 2011, 2, 827–836. [CrossRef]

48. Rosas-Ramírez, D.; Escandón-Rivera, S.; Pereda-Miranda, R. Morning Glory Resin Glycosides as α-Glucosidase Inhibitors: In Vitro and In Silico Analysis. *Phytochemistry* 2018, 148, 39–47. [CrossRef]

49. Bruhn, T.; Schaumloffel, A.; Hemberger, Y.; Bringmann, G. SpecDis: Quantifying the Comparison of Calculated and Experimental Electronic Circular Dichroism Spectra. *Chirality* 2013, 25, 243–249. [CrossRef]